Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, Director of the new Young Adults Cancers Initiative, and the Chair, Developmental Research Program for the GI SPORE, at the Vanderbilt-Ingram Cancer Center. Currently, she serves on the Scientific Review Committee and the Clinical Trials Shared Resource Oversite Committee. She continues to assume leadership positions devoted to clinical research. She has focused on the development of phase l-Ill clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.
Nationally, Dr. Eng has also been highly active serving on ASCO, ECOG, and SWOG. She has served on multiple committees for ASCO including the Career Development Committee, Education Committee for Colorectal Cancer; ASCO Scientific Program Committee Track Leader for the Gastrointestinal Cancer-Colorectal/Liver Track and served on the Steering Committee 2012-2015. She is the former Chairman of the Scientific Program Committee of the ASCO Gastrointestinal Cancer Symposium from 2012-2013 and Chairman, Steering Committee, Gl Cancers Symposium 2016. She was chosen for the ASCO Leadership Development Program and served on the ASCO Government Relations Committee; worked with the ASCO Cancer Prevention Committee on the consensus statement regarding HPV vaccination; served on the ASCO Nausea and vomiting Guidelines Committee, ASCO Taxonomy Task Force, ASCO Social Media Committee, and is currently on the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee. She was the co-chair of the SWOG Rectal/Anal Cancer Subcommittee and is currently the Vice-Chair for the SWOG GI Committee. She was the Chairman of the NCI Rectal/Anal Task Force (two terms) and currently serves on the NCI GI Steering Committee.
She has published in many peer reviewed journals including JCO, Lancet Oncology, Nature Review, The Annals of Oncology, Cancer, and Annals of Surgical Oncology. She has previously received an NCI grant “Administrative Supplements to the institutional CCSG grant to Support Biomarker Studies Associated with NCI-supported Clinical Trials of Immunotherapy". She was a co-Pl for the MD Anderson Moonshot for HPV-Associated Malignancies (Section Lead for the Rare Cancers subsection) and is a grant reviewer on the MD Anderson Colorectal Cancer Moonshot and the Sabine award. She has served as a consultant to the FDA and AHRQ, Cancer Research UK: Training & Career Development Board - Clinician Scientist Fellowship, the Italian Association for Cancer Research, the Dutch Digestive Foundation, the Stand Up to Cancer (SU2C) - Farrah Fawcett Foundation Joint Scientific Advisory Committee (JSACand is a grant review for the SWOG Impact Award.
Jordan Berlin, MD is an Ingram Professor of Cancer Research and is the Associate Director for Clinical Research at Vanderbilt Ingram Cancer Center (VICC). He is Director the Division of Hematology and Oncology at Vanderbilt University Medical Center (VUMC) and Director of Phase I research at VICC. He is a recognized expert in Gastrointestinal Cancers Translational Research and early phase drug development across a range of cancers, has been co-PI of the Vanderbilt GI SPORE and is the Chair of the ECOG-ACRIN GI Committee. He is past Chair of the Overall Program for the GI Cancers Symposium (aka ASCO GI) and served as chair of the Pancreas Cancer Task Force for the NCI GI Steering Committee. He holds a UM1 to conduct trials in the Early Therapeutics Clincial Trials Network and serves on the National Cancer Institute’s Investigational Drug Steering Committee. He is also chair of the NCCN Investigaotr Steering Committee and has served on multiple guidelines committees in the past.